OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantOS
Oxford Science Enterprises
oxfordscienceenterprises.com ↗Activity from announced rounds
Activity in this selectionBiotech
Venture building and investment across Oxford’s deep tech, life sciences and health technology ecosystem.
Turning scientific research into companies
Oxford Science Enterprises builds and funds companies from Oxford’s science ecosystem. It works with university researchers, technology hubs and independent scientific startups, combining company formation with investment from pre-seed through growth. Its stated sectors are deep tech, life sciences and health technology.
Activity recorded in RoundOS
Covered financings include Vivid Dx in diagnostics, Mirae in chronic care, ReEmerge in brain-injury rehabilitation, MCatalysis in fuels and events involving Oxford Quantum Circuits and Quantum Motion. These illustrate the range of recorded scientific businesses; OSE’s own directory describes its broader portfolio.
- Rounds participated in
- 7
- Confirmed lead rounds
- 0 5 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $517M 7 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionReEmerge, Inc.
ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.
$37MSeries A
ParticipantVivid Dx
Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions
$15MSeed
Role not disclosedMirae
AI-driven continuous care platform for autoimmune disease and other complex chronic conditions
$5.4MSeed
Role not disclosedMoa Technology
An agricultural biotechnology company focused on discovering novel mode of action herbicides
£22.2MSeries C
Role not disclosedRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedAllos AI
Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies.
$5MSeed
Role not disclosed